Company: EUDAW
Filing Date: 2025-06-24
Form Type: 424B5
Source: 0001641172-25-016185
Chunk: 14

Company: EUDA Health Holdings Ltd
Filing Date: 2025-06-24
Form: 424B5
Chunk 14
---
 the net proceeds of this offering and may not use them effectively.

We intend to use the net proceeds from this offering for general corporate purposes, including possible acquisitions or the expansion of our business and working capital. However, our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our ordinary shares. The failure by management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business and cause the price of our ordinary shares to decline. See “ Use of Proceeds” for further information.

You may experience immediate and substantial dilution in the book value per share of the ordinary shares you purchase.

Because the prices per share at which shares of our ordinary shares are sold in this offering may be substantially higher than the book value per share of our ordinary shares, you may suffer immediate and substantial dilution in the net tangible book value of the ordinary shares you purchase in this offering. The shares sold in this offering, if any, will be sold from time to time at various prices. After giving effect to the sale of our ordinary shares in the maximum aggregate offering amount of $10.0 million at an assumed offering price of $3.72 per share, the last reported sale price of our ordinary shares on Nasdaq on June 20, 2025, and after deducting estimated offering commissions payable by us, our net tangible book value as of December 31, 2024, would have been $6.3 million, or $0.16 per ordinary share. This represents an immediate increase in the net tangible book value of $0.24 per share to our existing stockholders and an immediate and substantial dilution in net tangible book value of $3.56 per share to new investors who purchase our ordinary shares in the offering. See “ Dilution” for a more detailed discussion of the dilution you may incur in connection with this offering.

Sales of a significant number of shares of our ordinary shares in the public markets, or the perception that such sales could occur, could depress the market price of our ordinary shares.

Sales of a substantial number of shares of our ordinary shares in the public markets could depress the market price of our ordinary shares and impair our ability to raise capital through the sale of additional equity securities. We cannot predict the effect that future sales of our ordinary shares would have on the market price of our ordinary shares.

Our failure to meet the Nasdaq listing requirements could result